Case File #01 — Process Validation Conclusion

The inspector pulled the validation protocol. Everything was executed. Then they asked: "Who authorized the acceptance criteria, and what was the documented rationale?"

That question ends careers. Not because the validation was wrong — but because the authorization logic was never captured as a formal record.

This case file gives you that record.

Section 01

What the Investigator Asked

483 Observation

During inspection of process validation records for Batch Series PV-2023-07 through PV-2023-09, the investigator noted the firm could not identify the individual responsible for authorizing the validation conclusion. The validation summary report contained data tables and acceptance criteria comparisons but did not document the decision owner, the evidence evaluated prior to authorization, or the risk basis used to determine the process was in a validated state.

Investigator Perspective

"When a validation conclusion is documented without identifying the decision owner or the evidence reviewed, investigators cannot determine whether the conclusion represents a controlled regulatory decision or a post-hoc documentation exercise."

A process validation conclusion is a formal regulatory determination — not a data summary. FDA investigators confirm not only that data met criteria, but that a qualified individual reviewed the totality of evidence, assessed residual risk, and authorized the specific conclusion that the process is capable of consistently producing product within predetermined specifications.

Absent that authorization record, the conclusion is an assertion. Assertions do not survive inspection.

Section 02

Evidence Present vs. Authorization Missing

What Existed	What Was Missing
✓ Three PPQ batches executed per protocol VP-2023-14	→ Identification of responsible decision authority
✓ All critical quality attributes within specification	→ Documentation of evidence reviewed prior to conclusion
✓ Critical process parameters monitored and within range	→ Risk determination supporting validated state claim
✓ Validation summary report issued and filed	→ Authorization statement linking evidence to conclusion
✓ QA signature present on report cover page	→ Timestamp of authorization moment

A QA signature on the cover page of a validation summary confirms the report was reviewed for completeness. It does not document who authorized the validation conclusion. Authorization identifies the accountable decision owner and the evidence reviewed prior to the decision — these are substantively different acts with different regulatory standing.

Section 03

The Operational Cost of the Missing Record

Following issuance of the 483 observation, the firm was required to conduct a retrospective review of all process validation conclusions issued in the prior 36 months. The review consumed approximately 340 person-hours across QA, manufacturing, and validation functions.

Regulatory significance: Failure to document validation conclusion authorization raises questions regarding quality unit oversight and process validation governance — elevating the observation from a documentation deficiency to a systemic quality system concern.

FDA 483 observation citing inadequate documentation of validation conclusion authorization
Retrospective review of 36 months of validation conclusions
CAPA initiated for authorization documentation failure
Validation SOP revision required with enhanced authorization requirements
Investigator requested evidence of decision ownership for all prior validation conclusions
Re-inspection commitment included in written FDA response

Section 04

What the Authorization Record Should Have Contained

The Decision Defense Record below is the authorization that should have existed at the moment this compliance decision was made — the inspection-ready record the firm could not produce.

Decision Defense Record · Authorization Artifact · ComplianceWorxs Inspection-Ready

Decision Context

Validation Protocol VP-2023-14 executed across three consecutive Process Performance Qualification batches for Metformin Hydrochloride Tablets 500 mg, manufactured at the Raleigh Oral Solid Dose Manufacturing Facility, under the Stage 2 PPQ requirements of the FDA Process Validation Guidance (2011).

Decision Statement

After reviewing the validation evidence listed below, I formally authorize the conclusion that Batch Series PV-2023-07 through PV-2023-09 demonstrates the manufacturing process for Metformin Hydrochloride Tablets 500 mg is in a validated state and is capable of consistently producing product meeting all critical quality attributes as defined in Validation Protocol VP-2023-14.

Regulatory Context

21 CFR 211.100(a) — Written procedures for production and process controls · 21 CFR 211.192 — Production record review · FDA Process Validation Guidance (2011) — Stage 2 PPQ authorization requirements · GAMP 5 — Risk-based validation framework

Evidence Considered

Batch manufacturing records: PV-2023-07, PV-2023-08, PV-2023-09 — all steps within parameters

CQA results: Assay 98.2%, 97.9%, 98.4% (spec 95.0%–105.0%); Dissolution >85% at 30 min (spec ≥80%)

Content uniformity RSD: 1.2%, 1.4%, 1.1% (spec ≤6.0%); Hardness and friability within specification

Statistical capability analysis: Cpk ≥ 1.67 for all critical parameters

Deviation log review: zero critical deviations across three-batch series

Equipment qualification status: IQ/OQ/PQ current and confirmed prior to PPQ execution

Risk Evaluation

Patient safety risk: LOW. All CQAs met acceptance criteria across the three-batch series. Process capability indices indicate operation well within specification limits. No patient safety risk identified from the totality of validation data reviewed.

Decision Owner

Michael Ramirez · Director, Process Validation · Apex Pharmaceutical Manufacturing Inc.

Inspection-Ready Rationale

Three-batch PPQ series demonstrates consistent performance across all CQAs and CPPs. Statistical analysis confirms capability. No critical deviations observed. The manufacturing process at the Raleigh Oral Solid Dose Manufacturing Facility is declared in a validated state. This authorization is defensible under direct regulatory scrutiny.

Section 05

How the Decision Should Have Been Authorized

A defensible validation conclusion requires an authorization record identifying the decision owner, enumerating the evidence reviewed, documenting the risk determination, and stating the formal conclusion in inspection-ready language — timestamped at the moment of authorization, not at the date of document approval.

Named decision owner with title and organizational accountability
Explicit enumeration of evidence reviewed prior to authorization
Risk evaluation statement addressing patient safety and process capability
Formal authorization statement in regulatory language
Timestamp of authorization moment (distinct from document signature date)
Reference to applicable regulatory standard and validation protocol

Without an authorization record, the validation conclusion cannot be defended under regulatory scrutiny — even if all validation data meet acceptance criteria.

Section 06

The Operational Correction

The validation summary report template must include a mandatory authorization section that cannot be bypassed. The report cannot be issued without a completed authorization record satisfying all required elements. This is a structural control, not a procedural reminder.

Authorization gate embedded in validation summary report template — cannot be bypassed
Mandatory decision owner identification with title and accountability statement
Evidence review requirement — list of reviewed records must be completed before issuance
QA verification checkpoint confirms authorization record completeness before report release
Validation conclusion authorization included in annual internal audit scope

Authorization must occur before the decision becomes a GMP record. Structural controls eliminate the gap. Procedural reminders do not. Decision Defense Records formalize that control and preserve the authorization trail investigators expect to see.